Search
aTyr Pharma Inc
ATYRAdd to Watchlist
0.590USD
-0.007-1.17%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
57.83MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.17%
5 Days
+5.04%
1 Month
+7.90%
6 Months
-24.68%
Year to Date
-24.68%
1 Year
-88.50%
Key Figures
0.597Open
0.624High
1.44MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.47%Turnover Ratio
0.597Prev. Close
0.571Low
662.21KTurnover
LossP/E Static
0.86P/B
0.00%Div Yield TTM
-79.18%ROA
7.29052wk High
0.35Volume Ratio
-64.02MNet Profit
98.03MShares
-0.7351EPS TTM
0.56Beta
-105.32%ROE
0.39552wk Low
8.95%Amplitude
100.00%Gross Margin
57.83MMarket Cap
2.27Reward/Risk
6.50%Risk Rate
TradingKey Stock Score of aTyr Pharma Inc
Currency: USD Updated: 2026-07-01Key Insights
aTyr Pharma Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 108 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.86.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
aTyr Pharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
aTyr Pharma Inc Highlights
StrengthsRisks
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
Growing
The company is in a growing phase, with the latest annual income totaling USD 190.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 190.00K.
Overvalued
The company’s latest PE is -0.80, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.62M shares, decreasing 28.92% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 17.02K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
4.857
Target Price
+713.86%
Upside Space
aTyr Pharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
aTyr Pharma Inc Info
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
Ticker SymbolATYR
CompanyaTyr Pharma Inc
CEOShukla (Sanjay S)
Websitehttps://www.atyrpharma.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52348.700
+94.400 (+0.18%)
29676.200
-123.100 (-0.41%)
7477.500
+2.000 (+0.03%)
14746.000
-609.000 (-3.97%)
68689.000
-796.000 (-1.15%)
6303.500
+28.100 (+0.45%)
67.454
-0.514 (-0.76%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4063.830
+33.060 (+0.82%)
FAQs
What is the current price of aTyr Pharma Inc (ATYR)?
The current price of aTyr Pharma Inc (ATYR) is 0.59.
What is the symbol of aTyr Pharma Inc?
The ticker symbol of aTyr Pharma Inc is ATYR.
What is the 52-week high of aTyr Pharma Inc?
The 52-week high of aTyr Pharma Inc is 7.29.
What is the 52-week low of aTyr Pharma Inc?
The 52-week low of aTyr Pharma Inc is 0.40.
What is the market capitalization of aTyr Pharma Inc?
The market capitalization of aTyr Pharma Inc is 57.82M.
Is aTyr Pharma Inc (ATYR) currently rated as Buy, Hold, or Sell?
According to analysts, aTyr Pharma Inc (ATYR) has an overall rating of Buy, with a price target of 4.86.
What is the Earnings Per Share (EPS TTM) of aTyr Pharma Inc (ATYR)?
The Earnings Per Share (EPS TTM) of aTyr Pharma Inc (ATYR) is -0.80.